The Europe Bacteriophage Market is experiencing significant growth, driven by advancements in phage therapy and agricultural applications. In 2025, the market is projected to reach USD 52.8 million, with expectations to grow to USD 118.4 million by 2035, reflecting a compound annual growth rate (CAGR) of 8.4% over the forecast period. This growth is primarily attributed to the increasing prevalence of antibiotic-resistant infections and the rising demand for alternative therapeutic solutions.

In the medical sector, bacteriophage therapy is gaining traction as an effective treatment for multidrug-resistant bacterial infections. The European Medicines Agency (EMA) has been actively involved in developing guidelines for the use of phage therapy, facilitating its integration into clinical practice. Additionally, several European countries have established phage therapy centers, contributing to the expansion of this market segment.

In agriculture, bacteriophages are being utilized to combat bacterial plant diseases, promoting sustainable farming practices. The European Union has recognized the potential of phage biocontrol and is supporting research initiatives to develop phage-based products for crop protection.